Recent large-scale genetic studies have proposed a new genetic classification of diffuse large B-cell lymphoma (DLBCL), which is clinically and biologically heterogeneous. However, the classification methods were complicated to be introduced into clinical practice. Here we retrospectively evaluated the mutational status and copy number changes of 144 genes in 177 Japanese patients with DLBCL, using targeted DNA sequencing. We developed a simplified algorithm for classifying four genetic subtypes—MYD88, NOTCH2, BCL2, and SGK1—by assessing alterations in 18 representative genes and BCL2 and BCL6 rearrangement status, integrating the significant genes from previous studies. In our cohort and another validation cohort from published data, the classification results in our algorithm showed close agreement with the other established algorithm. A differential prognosis among the four groups was observed. The NOTCH2 group showed a particularly poorer outcome than similar groups in previous reports. Furthermore, our study revealed unreported genetic features in the DLBCL subtypes that are mainly reported in Japanese patients, such as CD5-positive DLBCL and methotrexate-associated lymphoproliferative disorders. These results indicate the utility of our simplified method for DLBCL genetic subtype classification, which can facilitate the optimisation of treatment strategies. In addition, our study highlights the genetic features of Japanese patients with DLBCL.

Conflict of interest

The authors declare no conflict of interest.

Supporting Information

References

1Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016; 66: 443–59
10.3322/caac.21357
PubMed Web of Science® Google Scholar
2Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015; 125(1): 22–32.
10.1182/blood-2014-05-577189
CAS PubMed Web of Science® Google Scholar
3Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94(5): 604–16.
10.1002/ajh.25460
CAS PubMed Web of Science® Google Scholar
4Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017.
Google Scholar
5Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769): 503–11.
10.1038/35000501
CAS PubMed Web of Science® Google Scholar
6Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25): 1937–47.
10.1056/NEJMoa012914
PubMed Web of Science® Google Scholar
7Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1): 275–82.
10.1182/blood-2003-05-1545
CAS PubMed Web of Science® Google Scholar
8Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020; 37(4): 551–68.e514.
10.1016/j.ccell.2020.03.015
CAS PubMed Web of Science® Google Scholar
9Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378(15): 1396–407.
10.1056/NEJMoa1801445
CAS PubMed Web of Science® Google Scholar
10Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5): 679–90.
10.1038/s41591-018-0016-8
CAS PubMed Web of Science® Google Scholar
11Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017; 171: 481–94.e415.
10.1016/j.cell.2017.09.027
CAS PubMed Web of Science® Google Scholar
12Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020; 135(20): 1759–71.
10.1182/blood.2019003535
CAS PubMed Web of Science® Google Scholar
13Ren W, Ye X, Su H, Li W, Liu D, Pirmoradian M, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018; 131(24): 2670–81.
10.1182/blood-2017-11-817601
CAS PubMed Web of Science® Google Scholar
14Bassig BA, Cerhan JR, Au WY, Kim HN, Sangrajrang S, Hu W, et al. Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. Eur J Haematol. 2015; 95(5): 442–8.
10.1111/ejh.12513
CAS PubMed Web of Science® Google Scholar
15de Miranda NF, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014; 124(16): 2544–53.
10.1182/blood-2013-12-546309
CAS PubMed Web of Science® Google Scholar
16Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002; 99(3): 815–21.
10.1182/blood.V99.3.815
CAS PubMed Web of Science® Google Scholar
17Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008; 19(11): 1921–6.
10.1093/annonc/mdn392
CAS PubMed Web of Science® Google Scholar
18Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011; 22(7): 1601–7.
10.1093/annonc/mdq627
CAS PubMed Web of Science® Google Scholar
19Yamakawa N, Fujimoto M, Kawabata D, Terao C, Nishikori M, Nakashima R, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014; 41(2): 293–9.
10.3899/jrheum.130270
CAS PubMed Web of Science® Google Scholar
20Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013; 91(1): 20–8.
10.1111/ejh.12116
CAS PubMed Web of Science® Google Scholar
21Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007; 34(2): 322–31.
CAS PubMed Web of Science® Google Scholar
22Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019; 43(7): 869–84.
10.1097/PAS.0000000000001271
PubMed Web of Science® Google Scholar
23Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018; 131(21): 2307–19.
10.1182/blood-2017-11-764332
CAS PubMed Web of Science® Google Scholar
24Berti A, Felicetti M, Peccatori S, Bortolotti R, Guella A, Vivaldi P, et al. EBV-induced lymphoproliferative disorders in rheumatic patients: a systematic review of the literature. Joint Bone Spine. 2018; 85(1): 35–40.
10.1016/j.jbspin.2017.01.006
PubMed Web of Science® Google Scholar
25Inui Y, Matsuoka H, Yakushijin K, Okamura A, Shimada T, Yano S, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015; 56(11): 3045–51.
10.3109/10428194.2015.1022769
CAS PubMed Web of Science® Google Scholar
26Carreras J, Yukie Kikuti Y, Miyaoka M, Hiraiwa S, Tomita S, Ikoma H, et al. Genomic profile and pathologic features of diffuse large B-cell lymphoma subtype of methotrexate-associated lymphoproliferative disorder in rheumatoid arthritis patients. Am J Surg Pathol. 2018; 42(7): 936–50.
10.1097/PAS.0000000000001071
PubMed Web of Science® Google Scholar
27Runge HFP, Lacy S, Barrans S, Beer PA, Painter D, Smith A, et al. Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL). Br J Haematol. 2021; 192(1): 216–20.
10.1111/bjh.17132
PubMed Web of Science® Google Scholar
28Pedrosa L, Fernández-Miranda I, Pérez-Callejo D, Quero C, Rodríguez M, Martín-Acosta P, et al. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. Sci Rep. 2021; 11(1): 1886.
10.1038/s41598-020-80376-0
CAS PubMed Web of Science® Google Scholar
29Olkkonen VM, Li S. Oxysterol-binding proteins: sterol and phosphoinositide sensors coordinating transport, signaling and metabolism. Prog Lipid Res. 2013; 52(4): 529–38.
10.1016/j.plipres.2013.06.004
CAS PubMed Web of Science® Google Scholar
30Burgett AW, Poulsen TB, Wangkanont K, Anderson DR, Kikuchi C, Shimada K, et al. Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat Chem Biol. 2011; 7(9): 639–47.
10.1038/nchembio.625
CAS PubMed Web of Science® Google Scholar
31Dobashi A, Togashi Y, Tanaka N, Yokoyama M, Tsuyama N, Baba S, et al. TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis. Oncotarget. 2018; 9(28): 19555–68.
10.18632/oncotarget.24656
PubMed Google Scholar
32Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Purschke F, Sprute R, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015; 29(3): 677–85.
10.1038/leu.2014.264
CAS PubMed Web of Science® Google Scholar
33Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015; 6(8): 5615–33.
10.18632/oncotarget.3479
PubMed Google Scholar
34Miyazaki K, Yamaguchi M, Imai H, Kobayashi K, Tamaru S, Kobayashi T, et al. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. Int J Hematol. 2015; 102(2): 188–94.
10.1007/s12185-015-1812-2
CAS PubMed Web of Science® Google Scholar
35Suguro M, Tagawa H, Kagami Y, Okamoto M, Ohshima K, Shiku H, et al. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci. 2006; 97(9): 868–74.
10.1111/j.1349-7006.2006.00267.x
CAS PubMed Web of Science® Google Scholar
36Takeuchi T, Yamaguchi M, Kobayashi K, Miyazaki K, Tawara I, Imai H, et al. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Cancer. 2017; 123(7): 1166–73.
10.1002/cncr.30404
CAS PubMed Web of Science® Google Scholar
37Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011; 20(6): 728–40.
10.1016/j.ccr.2011.11.006
CAS PubMed Web of Science® Google Scholar
38Cao Y, Zhu T, Zhang P, Xiao M, Yi S, Yang Y, et al. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. Oncotarget. 2016; 7(50): 83294–307.
10.18632/oncotarget.13065
PubMed Google Scholar

Citing Literature

Volume195, Issue5

December 2021

Pages 731-742

Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort

Summary

Conflict of interest

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort

Summary

Conflict of interest

Supporting Information

References

Citing Literature

References

Related

Information